DeepWell Digital Therapeutics (DTx), which commercializes immersive medical media, and NeuFluent, its venture studio that develops neuroscience innovation, together announce that Dr. Russell Lonser will serve as the companies' global head of pharmaceutical technology.
SEATTLE, Oct. 1, 2024 /PRNewswire-PRWeb/ -- DeepWell Digital Therapeutics (DTx), which commercializes immersive medical media, and NeuFluent, its venture studio that develops neuroscience innovation, together announce that Dr. Russell Lonser will serve as the companies' global head of pharmaceutical technology. In this new role, Dr. Lonser will develop partnerships and clinical evidence at the intersection of neuro prosthetics, immersive medicine, and pharmaceutical solutions. He will work to blend devices, digital, traditional, and natural pharmaceuticals to shift how health and disease are managed. Dr. Lonser is professor and chair of the Department of Neurological Surgery at the Chronic Brain Injury College of Medicine Department of Neuroscience in the Brain and Spine Tumor Center at The Ohio State University College of Medicine and leader of the Gene Therapy Institute.
Deepening its medical team with the addition of Dr Lonser comes just a month after DeepWell received 510(k) clearance from the Food and Drug Administration (FDA) for its biofeedback (ABS) software development kit (SDK) for use in over-the-counter treatments for the reduction of stress and as an adjunctive treatment for high blood pressure, together with other pharmacological and/or nonpharmacological interventions. The technology is available to media companies to embed or use adjacently with their products for commercialization of video games and other immersive media as FDA-cleared digital therapeutics. Immersive media impacts both the mental and physical domains of healthcare and, in the future, provides the opportunity to work with brain monitoring, neuro prosthetics, smart AI, and big data to prolong health, treat disease, and enhance life for millions of people.
"Dr. Lonser is at the cutting edge of investigating and commercializing device combinations. Working with DeepWell technology, he will help us open the world of extrinsic stimulation in conjunction with implantable devices and pharma," said Dr. Sam Browd, co-founder of DeepWell DTx, a leading pediatric neurosurgeon at the University of Washington and advocate for Artificial Intelligence and Computational Brain Sciences for the American Association of Neurological Surgeons and Congress of Neurological Surgeons. Dr. Browd's partner, Chairman of NeuFluent Ryan Douglas, adds "Dr. Lonser's leadership will accelerate the physical and mental health treatments powered by this new technology. We're honored to have him on our team, Russ is a giant in the neuro space, has done amazing work to make The Ohio State University a world leader in neuro research, and is literally one of the 'fathers' of gene therapy."
"I joined the DeepWell-NeuFluent team because it is taking the most progressive approach to bringing together all aspects of neurological health care, with a fundamental eye on its accessibility," said Dr. Lonser.
Media featuring DeepWell technology can be available to consumers over the counter (without a prescription) and by doctors orders on mobile device platforms. The company is actively working with media companies to prepare solutions in advance of the Centers for Medicaid and Medicare Services (CMS) codes which allow Digital Mental Health Treatment (DMHT) devices to be reimbursable as a physician service beginning in 2025. The codes provide monetary incentives for companies to develop, doctors to recommend, and patients to use digital therapies that incorporate DeepWell technology.
The technology provides monitoring, recommendations and biostimulation in interactive media that activates the user's vagus nerve while greatly increasing patient engagement, reducing sympathetic nervous system activation, and improves resilience to reduce stress and hypertension. Immersive biofeedback-driven media increases consistent use for immediate and long-term mental and physical health benefits. The technology has been reviewed and endorsed by dozens of innovators in digital therapeutics, media, medicine, and mobile.
About DeepWell DTx
DeepWell DTx makes digital therapeutic technology that can be integrated with media to create new approaches for treating mental and physical health conditions. Launched in 2022, DeepWell holds several patents, with 20 more pending, for transforming media into medicine.
DeepWell DTx is part of NeuFluent, a venture studio developing neuroscience innovation -- novel components, systems, and processes for highly reliable interconnectivity that streams data to digitally native processing and communication platforms. NeuFluent technology promotes accelerated adoption of new behaviors, self-discovery, and learning. NeuFluent holds multiple patents in dynamically controlled shunts, distributed sensing and control, central nervous system monitoring and interventions, spinal fluid polarization, therapeutics augmentation, AI based managed care, brain computer interfaces, and more.
Media Contact
Lisbeth Marie LaBreche, LaBreche Inc., 1 6125782834, [email protected], LaBreche Inc.
SOURCE DeepWell Digital Therapeutics (DTx)
Share this article